Home Alzheimer’s Disease FDA Approves Selpercatinib for 3 RET-Positive Cancer Types

FDA Approves Selpercatinib for 3 RET-Positive Cancer Types

The FDA approved selpercatinib (Retevmo), the first of its kind, to treat non-small cell lung cancer (NSCLC), medullary thyroid cancer and other types of thyroid cancers with rearranged during transfection, or RET, alterations.

Selpercatinib is indicated for the following:
• NSCLC that has spread in adults
• Advanced medullary thyroid cancer (MTC) or MTC that has spread, in patients 12 and older who require systemic therapy
• Advanced RET fusion-positive thyroid cancer in patients aged 12 and older that requires systemic therapy that has stopped responding to radioactive iodine therapy or is not appropriate for radioactive iodine therapy

The FDA made its decision based on results from a trial that evaluated the agent in 105 adult patients with RET fusion-positive NSCLC who were previously treated with platinum chemotherapy; 143 patients with advanced or metastatic RET-mutant MTC…

Continue Reading to the Source

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Popular

Cause of Alzheimer’s disease traced to mutation in common enzyme

submitted by /u/scotsman81 Continue Reading to the Source

Reflections on Living With an Incurable Illness : braincancer

(I’ve checked with the moderators to make sure this is appropriate and a good fit for this subreddit. I'm a very private person, and...

This Foramen Magnum Meningioma almost killed me 18 years ago.

submitted by /u/dkrem Continue Reading to the Source

Patients, Family & Friends, and Healthcare professionals : braincancer

I am currently a PhD student based at the Marie Curie Palliative Care Research Centre at Cardiff University. My PhD is focussed on developing...

Recent Comments